European CHMP recommends approval of duvelisib for treatment of relapsed/refractory chronic lymphocytic leukaemia and refractory follicular lymphoma

Duvelisib, was granted positive opinion on the basis of studies which demonstrated improved survival without disease progression vs ofatumumab in adults with CLL who have received 2 or more prior lines of treatment.

Source:

European Medicines Agency